Eton Pharmaceuticals Net Borrowings Over Time
| ETON Stock | USD 15.03 0.67 4.27% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Eton Pharmaceuticals Performance and Eton Pharmaceuticals Correlation. Eton |
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eton Pharmaceuticals. If investors know Eton will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eton Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.13) | Earnings Share (0.26) | Revenue Per Share | Quarterly Revenue Growth (0.24) | Return On Assets |
The market value of Eton Pharmaceuticals is measured differently than its book value, which is the value of Eton that is recorded on the company's balance sheet. Investors also form their own opinion of Eton Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Eton Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eton Pharmaceuticals' market value can be influenced by many factors that don't directly affect Eton Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Eton Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Eton Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eton Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Net Borrowings Analysis
Compare Eton Pharmaceuticals and related stocks such as Connect Biopharma, Acumen Pharmaceuticals, and Nuvation Bio Net Borrowings Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CNTB | (334 K) | (334 K) | (334 K) | (334 K) | (334 K) | (334 K) | (334 K) | (334 K) | (334 K) | (445 K) | (538 K) | (805 K) | (805 K) | (805 K) | (724.5 K) | (760.7 K) |
| NUVB | 800 K | 800 K | 800 K | 800 K | 800 K | 800 K | 800 K | 800 K | 800 K | 14.4 M | 14.4 M | 14.4 M | 14.4 M | 14.4 M | 16.5 M | 8.4 M |
| ELDN | 2.9 M | 2.9 M | 2.9 M | 2.9 M | 2.9 M | 2.9 M | 2.9 M | 2.9 M | 2.9 M | 2.9 M | 2.9 M | 2.9 M | 2.9 M | 2.9 M | 2.6 M | 2.3 M |
| INBX | 14.1 M | 14.1 M | 14.1 M | 14.1 M | 14.1 M | 14.1 M | 14.1 M | (5 M) | (5.7 M) | 33.8 M | 41.4 M | 40 M | 128.9 M | 128.9 M | 148.2 M | 155.6 M |
| CELC | 7.5 M | 7.5 M | 7.5 M | 7.5 M | 7.5 M | 7.5 M | 7.5 M | 7.5 M | (3.3 K) | (5.7 K) | (5.8 K) | 14.3 M | 19.5 M | 19.5 M | 22.4 M | 23.6 M |
| REPL | 9.9 M | 9.9 M | 9.9 M | 9.9 M | 9.9 M | 9.9 M | 9.9 M | 9.9 M | 9.9 M | 10 M | (10.8 M) | (264 K) | (264 K) | (264 K) | (237.6 K) | (225.7 K) |
| LYRA | 500 K | 500 K | 500 K | 500 K | 500 K | 500 K | 500 K | 500 K | 500 K | 500 K | 500 K | 500 K | 500 K | 500 K | 450 K | 400 K |
| KRON | (72 K) | (72 K) | (72 K) | (72 K) | (72 K) | (72 K) | (72 K) | (72 K) | (72 K) | (30 K) | 151.2 M | (5 K) | (5 K) | (5 K) | (5.8 K) | (5.5 K) |
| GOSS | 40 K | 40 K | 40 K | 40 K | 40 K | 40 K | 40 K | 6 M | (40 K) | 28.2 M | 193.6 M | (5.8 M) | (5.8 M) | (5.8 M) | (6.7 M) | (6.3 M) |
| TARS | 2 M | 2 M | 2 M | 2 M | 2 M | 2 M | 2 M | 2 M | 2 M | 2 M | 20 M | 20 M | (875 K) | (875 K) | (1 M) | (955.9 K) |
| ALDX | (1.4 M) | (1.4 M) | (1.4 M) | (1.4 M) | (1.4 M) | (1.4 M) | (1.4 M) | (1.4 M) | (1.4 M) | 14.3 M | 14.3 M | 14.3 M | 14.3 M | 14.3 M | 16.5 M | 17.3 M |
| TVTX | 235.8 M | 235.8 M | 235.8 M | 235.8 M | 235.8 M | 235.8 M | 235.8 M | 235.8 M | 235.8 M | 104.9 M | 104.9 M | 104.9 M | 95 M | 95 M | 85.5 M | 117.5 M |
| BDTX | (50 K) | (50 K) | (50 K) | (50 K) | (50 K) | (50 K) | (50 K) | (50 K) | (50 K) | (50 K) | (50 K) | (50 K) | (50 K) | (50 K) | (45 K) | (47.2 K) |
Eton Pharmaceuticals and related stocks such as Connect Biopharma, Acumen Pharmaceuticals, and Nuvation Bio Net Borrowings description
The difference between the amount of new debt a company has taken on and the amount of debt it has paid off during a given period.My Equities
My Current Equities and Potential Positions
| Eton Pharmaceuticals | ETON |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | Illinois; U.S.A |
| Exchange | NASDAQ Exchange |
USD 15.03
Check out Eton Pharmaceuticals Performance and Eton Pharmaceuticals Correlation. To learn how to invest in Eton Stock, please use our How to Invest in Eton Pharmaceuticals guide.You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Eton Pharmaceuticals technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.